Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Henitz Erin Devay"'
Autor:
Bradley J. Monk, Trilok V. Parekh, Roland Elmar Knoblauch, P.S. Cheng, Weimin Li, A.S. Matos-Pita, Prafull Ghatage, Youn C. Park, Reyna Favis, Deborah Ricci, Andres Poveda, Henitz Erin Devay, Antonio Nieto
Publikováno v:
Annals of Oncology. 26:914-920
In this exploratory analysis, patients with recurrent ovarian cancer carrying BRCA1mut gene had improved outcomes with trabectedin + PLD treatment compared with PLD alone. Prospective evaluation of BRCA status is likely an important evaluation for DN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6b2be917e4ce84e561495b43235ae1c
https://doi.org/10.1093/annonc/mdv071
https://doi.org/10.1093/annonc/mdv071
Autor:
Michael Crump, Ofer Shpilberg, Sven de Vos, Dixie Lee Esseltine, Adriana Teixeira, Weimin Li, Joanna Romejko-Jarosinska, Adriana Scheliga, George Mulligan, Yusri Elsayed, Andrew Cakana, Osmanov Ea, Helgi van de Velde, Panteli Theocharous, Fritz Offner, Henitz Erin Devay, Michael E. Schaffer, Bertrand Coiffier, Simon Rule, Jayaprakash Karkera, Alice Shapiro, Jiri Mayer, Deborah Ricci, Dana Gaffney, Xiaonan Hong, Reyna Favis, Pier Luigi Zinzani
Publikováno v:
Clinical Cancer Research. 19:2551-2561
Purpose: Identify subgroups of patients with relapsed/refractory follicular lymphoma deriving substantial progression-free survival (PFS) benefit with bortezomib–rituximab versus rituximab in the phase III LYM-3001 study. Experimental Design: A tot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe20d8672aa661248cb925a0d9b9ef7
https://doi.org/10.1158/1078-0432.ccr-12-3069
https://doi.org/10.1158/1078-0432.ccr-12-3069
Autor:
Christopher J. Logothetis, Charles J. Ryan, Robert Jones, Deborah Ricci, Jose Maria M. Piulats Rodriguez, Henitz Erin Devay, John J. Gullo, Henrik Suttmann, Alfons J.M. van den Eertwegh, Gerhardt Attard, Weimin Li, Joan Carles, Eleni Efstathiou, Johann S. de Bono, Dirk Schrijvers, Howard I. Scher, Michael Gormley, Thomas W. Griffin, Dana E. Rathkopf
Publikováno v:
Journal of Clinical Oncology. 32:5058-5058
5058 Background: AA is metabolized to abiraterone, a CYP17 inhibitor that blocks testicular, adrenal, and tumoral androgen biosynthesis. AA is approved for the treatment of metastatic castration-re...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61e43ffe937e20fb58b1d574b15c0398
https://doi.org/10.1200/jco.2014.32.15_suppl.5058
https://doi.org/10.1200/jco.2014.32.15_suppl.5058
Autor:
Simon Rule, Pier Luigi Zinzani, Jayaprakash Karkera, Adriana Scheliga, Adriana Teixeira, Weimin Li, Jan Walewski, Yusri Elsayed, Alice Shapiro, Dana Gaffney, Andrew Cakana, Osmanov Ea, Henitz Erin Devay, Xiaonan Hong, Deborah Ricci, Helgi van de Velde, Dixie-Lee Esseltine, Reyna Favis, Sven de Vos, Michael Crump, Bertrand Coiffier, Panteli Theocharous, Fritz Offner, Ofer Shpilberg, George Mulligan
Publikováno v:
Blood. 118:265-265
Abstract 265 Background: Treatment goals in patients with relapsed FL are to prolong PFS and improve overall survival (OS). To optimize treatment for individual patients, identification of subgroups most likely to benefit from a specific therapy is i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a3c02f05f096b3d72ec7bb7fc33507d
https://doi.org/10.1182/blood.v118.21.265.265
https://doi.org/10.1182/blood.v118.21.265.265